PepGen

plan B fail reroute road path trail miss
Biotech

PepGen ends all DMD work after phase 2 trial falls flat

PepGen’s exon 51-skipping oligonucleotide PGN-EDO51 only increased dystrophin to 0.59% of normal levels in four patients in the 10-mg/kg cohort.
Darren Incorvaia May 28, 2025 5:30pm
Stop sign

PepGen pauses UK arm of DMD trial that's already on hold in US

Mar 4, 2025 10:25am
FDA stop sign

FDA hits pause on another of PepGen's muscular dystrophy trials

Dec 16, 2024 9:45am
Paragliding over the cliffs Fort Funston San Francisco

BioMarin builds exec team with biotech vets—Chutes & Ladders

Aug 23, 2024 8:30am
Alps parachute rainbow mountains

J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders

Jun 14, 2024 8:30am
steps race jump stairs climb

PepGen gains a little pep in its step as FDA clears trial hold

Oct 12, 2023 7:00am